Edition:
United Kingdom

Jounce Therapeutics Inc (JNCE.OQ)

JNCE.OQ on NASDAQ Stock Exchange Global Select Market

14.14USD
8 Dec 2017
Change (% chg)

-- (--)
Prev Close
$14.14
Open
--
Day's High
--
Day's Low
--
Volume
--
Avg. Vol
59,033
52-wk High
$29.29
52-wk Low
$11.05

Summary

Name Age Since Current Position

Perry Karsen

62 2016 Chairman of the Board

Richard Murray

58 2014 President, Chief Executive Officer, Director

James Allison

Co-Founder

Thomas Gajewski

Co-Founder

Drew Pardoll

Co-Founder

Padmanee Sharma

Co-Founder

Kimberlee Drapkin

49 2015 Chief Financial Officer, Treasurer

Deborah Law

2015 Chief Scientific Officer

Elizabeth Trehu

56 2015 Chief Medical Officer

Luis Diaz

2017 Director

Barbara Duncan

52 2016 Independent Director

J. Duncan Higgons

62 2015 Independent Director

Robert Kamen

72 2013 Independent Director

Cary Pfeffer

2016 Independent Director

Robert Tepper

62 2013 Independent Director

Biographies

Name Description

Perry Karsen

Mr. Perry Karsen is the Chairman of the Board of Jounce Therapeutics, Inc. Mr. Karsen has served as a director on our board of directors since January 2016, and as the chairman of our board of directors since April 2016. Mr. Karsen is a venture partner with Third Rock Ventures, LLC, which he joined in 2016. Previously, Mr. Karsen was the chief executive officer of the Celgene Cellular Therapeutics division of Celgene Corporation, or Celgene, from 2013 until his retirement in 2015. Mr. Karsen served as executive vice president and chief operations officer of Celgene from 2010 to 2013, and as senior vice president and head of worldwide business development of Celgene from 2004 to 2009. Mr. Karsen was chief executive officer of Pearl Therapeutics Inc., from 2009 to 2010. Earlier in his career, Mr. Karsen held executive positions at Human Genome Sciences, Inc., Bristol-Myers Squibb Co., Genentech, Inc. and Abbott Laboratories. He is a member of the boards of directors of publicly traded life sciences companies Intellia Therapeutics, Inc. where he serves as chairman of the board, OncoMed Pharmaceuticals, Inc. and Voyager Therapeutics, Inc. Mr. Karsen received a Masters of Management from Northwestern University's Kellogg Graduate School of Management, a Masters of Arts in Teaching of Biology from Duke University and a B.S. in Biological Sciences from the University of Illinois, Urbana-Champaign.

Richard Murray

Dr. Richard Murray, Ph.D. is the President, Chief Executive Officer and Director of Jounce Therapeutics, Inc. Mr. Murray has served as our president, chief executive officer and a director on our board of directors since July 2014. Prior to joining Jounce, Dr. Murray served as senior vice president of biologics and vaccines research and development at Merck & Co. from 2009 to 2014, where he had responsibilities for the advancement of biologics and vaccines, including Merck's cancer immunotherapy pipeline. From 2008 to 2009, Dr. Murray served as an advisor to venture capital and life science investors. From 2003 to 2008, he served in a variety of roles at PDL Biopharma Inc., or PDL, initially as vice president of research to executive vice president and chief scientific officer. He also served as a director of PDL from 2007 to 2008. Earlier in his career, Dr. Murray was a co-founder and served as vice president of research at Eos Biotechnology, Inc. from 1998 to 2003. Dr. Murray holds a Ph.D. in microbiology and immunology from the University of North Carolina at Chapel Hill and a B.S. in microbiology from the University of Massachusetts, Amherst.

James Allison

Dr. James P. Allison, Ph.D. is a co-founder of Jounce Therapeutics and currently serves as chair of The University of Texas MD Anderson Cancer Center Department of Immunology and director of the Immunotherapy Platform. A leading tumor immunologist, Dr. Allison has a longstanding interest in mechanisms of T-cell development and activation, the development of novel strategies for tumor immunotherapy and is recognized as the first person to isolate the T-cell antigen receptor protein. His research led to the clinical development of ipilimumab (Yervoy™), which was approved in 2011 by the FDA for the treatment of metastatic melanoma. Previously, he was director of the Ludwig Center for Cancer Immunotherapy and the chair of the immunology program at the Memorial Sloan-Kettering Cancer Center, as well as the David H. Koch Chair in Immunologic Studies and attending immunologist at Memorial Sloan-Kettering Cancer Center. Dr. Allison is a member of the National Academy of Sciences and the Institute of Medicine, and is a fellow of the American Academy of Microbiology and the American Association for the Advancement of Science. Previously, he served as president of the American Association of Immunologists. He has received numerous awards, including the Centeon Award for Innovative Breakthroughs in Immunology, the William B. Coley Award for Distinguished Research in Basic and Tumor Immunology, the AAI-Dana Award in Human Immunology Research and the C. Chester Stock Award for Distinguished Achievement in Biomedical Research. Dr. Allison recently received an AACR/SU2C/CRI cancer immunotherapy dream team grant, for which he will serve as the Dream Team leader. Dr. Allison received his B.S. in microbiology and his Ph.D. in biological sciences from the University of Texas.

Thomas Gajewski

Dr. Thomas F. Gajewski, M.D. Ph.D. is a scientific co-founder of Jounce Therapeutics and currently serves as professor, departments of pathology and medicine, section of hematology/oncology at the University of Chicago. There, he is leader of the immunology and cancer program of the Cancer Center, and also directs the Melanoma Oncology Clinic. Dr. Gajewski is the immediate past president of the Society for Immunotherapy of Cancer and serves as an editor of Cancer Research and JITC. His laboratory studies the molecular and cellular regulation of T lymphocyte activation and differentiation, and in turn applies this information to preclinical and clinical efforts to promote anti-tumor immunity in vivo. Dr. Gajewski is committed to investigating and developing new treatments for patients with melanoma, with a special interest in the development of immunotherapies against the disease. Dr. Gajewski also leads development of immune-based therapies for other cancers, using new laboratory data on how the immune system is regulated to develop novel clinical trials. He has served on the program committees for the American Society for Clinical Oncology (ASCO) and the American Association for Cancer Research (AACR).

Drew Pardoll

Dr. Drew Pardoll, M.D. Ph.D. is a Co-Founder of Jounce Therapeutics, Inc. Dr. Pardoll is a scientific co-founder of Jounce Therapeutics and an Abeloff Professor of oncology, medicine, pathology and molecular biology and genetics at the Johns Hopkins University School of Medicine. He is also director of cancer immunology in the Sidney Kimmel Comprehensive Cancer Center. Dr. Pardoll has published more than 250 papers and more than 20 book chapters on the subject of T cell immunology and cancer vaccines. He has served on the editorial board of the Journal of the National Cancer Institute and Cancer Cell, and has served as a member of scientific advisory boards for the Cancer Research Institute, the University of Pennsylvania Human Gene Therapy Gene Institute, Biologic Resources Branch of the National Cancer Institute, Harvard-Dana Farber Cancer Center, Cerus Corporation, Global Medical Products Corporation, Genencor Corporation, CellGenesys Corporation, Mojave Therapeutics, the American Association of Clinical Oncology and the American Association of Cancer Research. Dr. Pardoll has made a number of basic advances in cellular immunology, including the discovery of gamma – delta T cells, NKT cells and interferon-producing killer dendritic cells. Over the past two decades, Dr. Pardoll has studied molecular aspects of dendritic cell biology and immune regulation, particularly related to mechanisms by which cancer cells evade elimination by the immune system. He is an inventor of a number of immunotherapies, including GVAX cancer vaccines and Listeria monocytogenes based cancer vaccines. Dr. Pardoll’s basic immunology discoveries include the identification of ?d-T cells, NKT cells and IKDC. Dr. Pardoll completed his MD, PhD, medical residency and oncology fellowship at Johns Hopkins University.

Padmanee Sharma

Dr. Padmanee Sharma, M.D. Ph.D. is a co-founder of Jounce Therapeutics and currently serves as scientific director and professor in the departments of genitourinary medical oncology and immunology at The University of Texas MD Anderson Cancer Center. Dr. Sharma is a medical oncologist and immunologist, and is currently the principal investigator of several immunotherapy clinical trials, which allow her to further investigate immune responses and pathways that are critical for eliciting anti-tumor responses and clinical benefit in cancer patients. Dr. Sharma has received numerous awards in her field including a Department of Defense (DOD) Idea Development Award (2010), a Cancer Prevention Research Institute of Texas (CPRIT) Individual Investigator Award (2011), a National Institute of Health (NIH/NCI) R01 Award (2012) and an AACR-CRI-SU2C Immunotherapy dream team grant (2013). Dr. Sharma holds a Ph.D. in immunology and an M.D. from Pennsylvania State University. She also holds a B.A. in biology and an M.A. in biotechnology from Boston University.

Kimberlee Drapkin

Ms. Kimberlee Cobleigh Drapkin, CPA is the Chief Financial Officer and Treasurer of Jounce Therapeutics, Inc. Ms. Drapkin has served as our chief financial officer since August, 2015, and our treasurer since February 2013. From 2009 to 2015, Ms. Drapkin was the owner of KCD Financial LLC, through which she served as our interim chief financial officer from 2012 to August 2015, and consulted for numerous biotechnology companies. Previously, Ms. Drapkin served as the chief financial officer of Predix Pharmaceuticals holdings, Inc., or Predix, from 2005 to 2006, and, after Predix was acquired by EPIX Pharmaceuticals, Inc., or EPIX, as chief financial officer of EPIX from 2006 to 2009. Earlier in her career, from 1995 to 2005, Ms. Drapkin served in a variety of roles at Millennium Pharmaceuticals, Inc., including as director of finance. Ms. Drapkin began her career at PricewaterhouseCoopers LLP and holds a B.S. in accounting from Babson College.

Deborah Law

Dr. Deborah Law, D. PHIL., is the Chief Scientific Officer at Jounce Therapeutics, Inc. Debbie Law brings to Jounce nearly two decades of experience in biologics drug discovery and development, particularly in the fields of oncology and immunology. Dr. Law joined Jounce from Merck, where she most recently served as vice president of therapy area biology for immunology, oncology and immunomodulators. There, she was responsible for bringing cancer immunotherapy compounds from discovery to the clinic. Prior to Merck, Dr. Law served as the chief scientific officer for Ablynx n.v. and held various research positions in biotechnology companies including PDL Biopharma, EOS Biotechnology and Cor Therapeutics. Dr. Law holds a B.S. in immunology from Glasgow University, a D. Phil. in immunology from Oxford University and pursued postdoctoral research at University of California San Francisco.

Elizabeth Trehu

Dr. Elizabeth G. Trehu, M.D. is the Chief Medical Officer of the Company. Dr. Trehu joined Jounce as our chief medical officer in November 2015. Prior to joining Jounce, Dr. Trehu served as the chief medical officer of Promedior, Inc. from 2012 to 2015. Previously, Dr. Trehu served as vice president, product development and medical affairs for Infinity Pharmaceuticals, Inc. from 2010 to 2012. Earlier in her career, Dr. Trehu served in a variety of roles for Genzyme Corporation, including as the vice president and general manager, hematology from 2009 to 2010, vice president and general manager of Clolar from 2008 to 2009 and vice president, global medical affairs of Genzyme Oncology from 2006 to 2008. Previously, Dr. Trehu served from 2002 to 2006 in a variety of positions at Millennium Pharmaceuticals, Inc., including as vice president of oncology global medical affairs in 2006. Dr. Trehu holds an M.D. from the New York University School of Medicine and an A.B. in English from Princeton University.

Luis Diaz

Dr. Luis A. Diaz, Jr. M.D., serves as Director of the Company. Dr. Diaz has served as the Head of the Solid Tumor Oncology division and a faculty member at the Memorial Sloan Kettering Cancer Center since December 2016. From 2004 to December 2016, Dr. Diaz was a faculty member and physician at Johns Hopkins University School of Medicine. Dr. Diaz is also a founder and board member, and from 2010 to 2016 served as President, Chief Executive Officer and Chief Medical Officer, of Personal Genome Diagnostics Inc., a private cancer genome analysis company. He received his M.D. from the University of Michigan, where he also received his B.A. in Microbiology.

Barbara Duncan

Ms. Barbara G. Duncan is an Independent Director of the Company. She served as a director on our board of directors since May 2016. Ms. Duncan served as the chief financial officer of Intercept Pharmaceuticals Inc. from 2009 to 2016 and as treasurer from 2010 to 2016. From 2001 to 2009, Ms. Duncan served as chief financial officer and then chief executive officer at DOV Pharmaceutical, Inc. Previously, Ms. Duncan served as a vice president of Lehman Brothers Inc. in its corporate finance division from 1998 to 2001. She serves on the board of directors of Adaptimmune Therapeutics plc, Aevi Genomic Medicine, Inc., Innoviva, Inc. and ObsEva SA and the boards of directors of other private companies. Ms. Duncan holds an M.B.A. from the Wharton School, University of Pennsylvania and a B.S. degree from Louisiana State University.

J. Duncan Higgons

Mr. J. Duncan Higgons is an Independent Director of the Company. He has served as a director on our board of directors since November 2015. Mr. Higgons recently served as chief operating officer of Agios Therapeutics, Inc., or Agios, from 2009 to 2016. Prior to joining Agios, Mr. Higgons served as executive vice-president, and interim president and chief executive officer at Archemix Corporation, or Archemix, from 2006 to 2009. Prior to Archemix, Mr. Higgons served as the chief commercial officer at TransForm Pharmaceuticals, Inc., a privately-held biotechnology company, which was acquired by Johnson & Johnson Company. Mr. Higgons holds a B.Sc. in Mathematics from King's College University of London and a M.Sc. in Economics from London Business School.

Robert Kamen

Dr. Robert Kamen, Ph.D. is an Independent Director of the Company. He has served as a member of our board of directors since June 2013. Dr. Kamen also served as our interim chief technology officer from 2013 to 2015. Dr. Kamen is an entrepreneur in residence at Third Rock Ventures, LLC, which he joined in 2010. From 2005 to 2010, Dr. Kamen served as the chairman of BioAssets Development Corporation. From 2002 to 2008, Dr. Kamen served as executive-in-residence at Oxford Bioscience Partners. From 2001 to 2002 he served as president of Abbot Laboratories' Abbot Bioresearch Center and as a member of the Abbot Pharma Executive Management Committee. From 1991 to 2001, he served as the president of BASF Bioresearch Corporation. Dr. Kamen serves on the boards of directors for numerous companies, including BioAssets Development Corporation, Inc., EpimAb Biotherapeutics, Inc., Harbour Antibodies BV, Lycera Corporation, Opsonic Therapeutics Inc. and Neon Therapeutics, Inc. Dr. Kamen holds a Ph.D. in biochemistry and molecular biology from Harvard University and a B.S. in biophysics from Amherst College.

Cary Pfeffer

Dr. Cary G. Pfeffer, M.D. is an Independent Director at Jounce Therapeutics, Inc. has served as a director on our board of directors since February 2013. Previously, Dr. Pfeffer served as the chairman of our board from 2014 to 2016, and as our interim chief executive officer from 2013 to 2014. Dr. Pfeffer is a partner at Third Rock Ventures, LLC, which he joined in 2007. Dr. Pfeffer was the interim chief executive officer of Neon Therapeutics, Inc. from 2015 to 2016. Dr. Pfeffer served at Biogen Inc. from 1992 to 2002 in a variety of domestic and international executive management roles. Dr. Pfeffer serves on the boards of directors for Ablexis, LLC, Edimer Pharmaceuticals, Inc., and Neon Therapeutics, Inc. where he serves as chairman of the board. Dr. Pfeffer received an M.B.A. from the Wharton School, an M.D. from the University of Pennsylvania School of Medicine and a B.A. in biochemistry from Columbia University.

Robert Tepper

Dr. Robert I. Tepper is an Independent Director of the Company.He has served as a member of our board of directors since February 2013. Previously, Dr. Tepper served as our interim chief scientific officer from 2013 to 2015. Since 2007, Dr. Tepper has served as a partner at Third Rock Ventures, LLC, which he co-founded in 2007. Since 2014, Dr. Tepper is currently the interim chief scientific officer of Neon Therapeutics, Inc. Prior to joining Third Rock Ventures, LLC, Dr. Tepper held multiple positions at Millennium Pharmaceuticals, Inc., including service as president of research and development from 2002 to 2007, executive vice president of discovery from 2001 to 2002 and chief scientific officer from 1999 to 2002. Dr. Tepper serves on the boards of directors for numerous companies, including Alcresta, Inc., Allena Pharmaceuticals, Inc., Constellation Pharmaceuticals, Inc., Kala Pharmaceuticals, Inc., and Neon Therapeutics, Inc. Previously, Dr. Tepper served on the boards of Bluebird Bio, Inc. and Alnara Pharmaceuticals, Inc. Dr. Tepper received an M.D. from Harvard Medical School and an A.B. in biochemistry from Princeton University.